Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

NCT00027690 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

NIH

Sponsor class

Conditions

Recurrent Uterine Corpus Carcinoma

Interventions

DRUG: Gefitinib
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]